Julie Scallen > Latham & Watkins LLP > Boston, United States > Lawyer Profile

Latham & Watkins LLP
200 CLARENDON STREET
BOSTON MA 02116
MASSACHUSETTS
United States

Work Department

Julie Scallen is a partner in the Boston office of Latham & Watkins and serves as Corporate Department Chair for the Boston office. She focuses her practice on mergers and acquisitions and private equity transactions. Ms. Scallen represents public and private companies and private equity funds in acquisitions, leveraged buyouts, dispositions, private equity and venture capital financings, strategic alliances, joint ventures and licensing transactions.

Lawyer Rankings

United States > Healthcare > Life sciences

(Leading partners)

Julie Scallen – Latham & Watkins LLP

Latham & Watkins LLP works with a number of major players in the life sciences industry on transactions in the sector, handling both M&A and IPOs, in addition to assisting with business combinations and licensing deals. In addition to transactional expertise, the practice is adept at overseeing patent protection strategies and litigation for pharma, biotech and medical devices companies. In Washington DC, John Manthei chairs the firm’s global life sciences group, specializing in the FDA regulatory process alongside vice chair Ben Haas, while also advising on the marketing of drugs and representing clients in Administrative Procedures Act litigation. Further litigation expertise comes in the shape of New York’s Arlene Chow and Chicago-based Terra Reynolds, with the former handling patent disputes concerning small molecule drugs and biologics, and the latter focusing on white collar defence and government investigations. In Silicon Valley, Shayne Kennedy is noted for his capital markets practice, advising on public and private securities offerings by life sciences clients. Boston’s Julie Scallen oversees both M&A and private equity transactions, and Elizabeth Richards, William McConagha and Jennifer Bragg, based in the capital, assist with FDA and DEA product testing and approval procedures. Judith Hasko has left the firm.